Earnings Ahead

SGMO - Sangamo Therapeutics

1.435 0.045 3.24

  1. Home
  2. Healthcare
  3. SGMO
Sangamo Therapeutics

Sangamo Therapeutics

About

Profile

Sangamo Therapeutics is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Headquarters

Richmond, California, United States

Intraday

High
-
Low
-

52-week

High
-
Low
-

SGMO



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Sangamo Therapeutics to undergo restructuring; laying off 27% of workforce
  • Sangamo Therapeutics Q1 2023 Earnings Preview
  • Gene editing stocks rally as Wall Street turns bullish
  • Sangamo down post-market as Novartis, Biogen end collaborations
  • Sangamo, Protagonist, and Eiger among biotechs with exposure to Silicon Valley Bank
  • Sangamo Therapeutics decides not to proceed with public offering
  • Sangamo gains 11% as Wedbush upgrades on Fabry disease candidate
  • Sangamo Therapeutics rises 5% on Q4 2022 earnings beats
  • Sangamo Therapeutics Q4 2022 Earnings Preview
  • Sangamo Therapeutics GAAP EPS of -$0.32 beats by $0.04, revenue of $27.23M beats by $0.37M
  • Sangamo Therapeutics GAAP EPS of -$0.34 beats by $0.02, revenue of $26.5M misses by $0.29M
  • Sangamo Therapeutics Q3 2022 Earnings Preview
  • Pfizer, Sangamo reopen recruitment for late-stage trial of hemophilia A gene therapy
  • Sangamo gene therapy for Fabry disease shows promise in phase 1/2 trial
  • Biotech in recovery; but Piper Sandler cites negative fund flows
  • Sangamo Therapeutics GAAP EPS of -$0.29 beats by $0.06, revenue of $29.38M beats by $4.75M
  • Sangamo Therapeutics Q2 2022 Earnings Preview
  • Sangamo's TX200 gets orphan drug tag in EU for use in organ transplant
  • SGMO, IMGN and BPOP are among after hour movers
  • Sangamo Therapeutics begun at neutral at Wedbush on 'frontrunner' Fabry candidate

Earnings History

Date EPS / Forecast Revenue / Forecast
February 24, 2022 -0.26 / -0.3455 28M / 26.82M Beat!
November 4, 2021 -0.33 / -0.3369 28.56M / 25.96M Beat!
August 5, 2021 -0.33 / -0.3131 27.87M / 26.53M Beat!
May 4, 2021 -0.32 / -0.2936 26.28M / 28.49M
February 24, 2021 -0.29 / -0.2127 25.8M / 31.42M
November 4, 2020 -0.01 / -0.242 57.76M / 26.55M Beat!
August 5, 2020 -0.26 / 0.11 21.55M / 102.71M Beat!
May 11, 2020 -0.37 / -0.28 13.08M / 22.74M
February 28, 2020 0.04 / -0.33 54.85M / 15.54M Beat!
February 7, 2020 - / -0.33 - / 15.54M
November 6, 2019 -0.24 / -0.34 21.96M / 12.16M Beat!
August 7, 2019 -0.26 / -0.36 17.55M / 13.58M Beat!
May 8, 2019 -0.41 / -0.25 8.07M / 23.1M
February 28, 2019 -0.18 / -0.21 26.84M / 22.51M Beat!
November 8, 2018 -0.13 / -0.15 23.56M / 26.96M
August 8, 2018 -0.17 / -0.15 21.42M / 21.86M
May 8, 2018 -0.23 / 0.48 12.64M / 53.09M
February 22, 2018 -0.15 / -0.18 13.08M / 11.43M Beat!
November 9, 2017 -0.15 / -0.19 11.81M / 10.36M Beat!
August 9, 2017 -0.17 / -0.19 8.25M / 5.98M Beat!